It’s been eight years since the AABB-CAP-ACOG working party first recommended RHD genotyping for patients with weak D phenotypes; how are we doing, and what are we finding? This session will discuss the identification of weak D phenotypes in manual and automated patient test methods and synthesize lessons learned from genotyping weak D phenotypes found among over a million patients in the US and Canada in published series. We will describe the current American status of RHD genotyping services, how serological and molecular methods influence the RHD genotyping findings, what are the most frequent partial RHD variants seen in these patients, and what is known about their risk for allo-anti-D. If you and your care providers have questions about weak D phenotypes, when to obtain genotyping, and what the genotypes mean, we’ll provide answers in an efficient interactive format geared to practical application.
Identify manual and automated weak D serological criteria for obtaining RHD genotyping
Discuss the influences of serological methods, genotyping techniques and patient race/ethnicities on RHD genotyping results
Describe which weak partial RHD variants are at most risk for anti-D formation
Review how to apply RHD genotyping results to Rh Immune Globulin therapy and RhD-negative transfusions
Professor of Pathology,
Feinberg School of Medicine, Northwestern University
MS, MASCP, MT(ASCP)SBB,
Adjunct Assistant Professor,
University of Pennsylvania
Sandra Nance, MS, MASCP, MT(ASCP)SBB:
BioRad: Honoraria (Terminated, January 1, 2023); Grifols: Honoraria (Terminated, January 1, 2023); QuidelOrtho: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing)
Glenn Ramsey, MD:
Immucor, Inc: Speaker's Bureau (Ongoing)
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.